LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies

LAVA Therapeutics N.V. announced that the US FDA has cleared its investigational new drug (IND) application for LAVA-051, the company’s lead product candidate for the treatment of relapsed or refractory chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.